 vessel formation in other settings. This is an open label, non randomized, Phase I dose escalating study of rhIL-12 administered by intraperitoneal (IP) infusion in adult male or female patients with measurable disseminated intraperitoneal cancer that is residual, recurrent or metastatic. Neither a control or placebo group will be utilized.
vessel formation in other settings. This is an open label, non randomize, Phase I drug escalate study of rhIL-12 administered by intraperitoneal (IP) infusion in adult male or female patients with measurable circulate intraperitoneal cancer that is residual, recurrent or metastatic. Neither a control or placebo group will be utilized.
 vedsel formation in other rettings. This is an opxn labem, non ravdomized, Phase I dose escalaving studt of rhIL-12 administered by intraieritoneao (IP) unfusion ii adult male od femclx patients with measurabla disseminated ivtxaperitoneal cancer that is residual, recurrrnh or metastatis. Neptrer z control or placebo group will be utiliztd.
vessel formation in other settings. This is label, randomized, Phase dose escalating study (IP) in adult male female patients with disseminated intraperitoneal cancer that is residual, or metastatic. Neither a control or placebo group will be utilized.
 vessel formation in other setTings. This iS an opEn lAbeL, nOn raNdomIzed, Phase I dose EScalAting study of rhIL-12 adminiStereD bY IntrAPeRitonEal (IP) inFUsION in AdUlT maLe OR fEmale PatIents wiTh measurabLe dIsSeminated intRApEritoneal cAncEr that is resiDuaL, recurReNt oR MetasTatIc. NeiTher a cONtrol oR placebo gRoUP will bE UtilizeD.
 vessel formation in other  settings.  This  is  an  o penlabe l, non randomi z ed,Phase I dose escalatin g stu dy of r h IL -12 a dminist e re d byin tr ape ri t on eal ( IP)  infusi on in adul t m al e or femalep at ients with  me asurable dis sem inated  i ntr a perit one al ca ncer t h at isresidual,  r e curren t  or met a s ta tic.  Neither a contro l  o r  placebo group  willbe ut i l ize d.
 vessel_formation in_other settings. This is_an open_label,_non randomized,_Phase_I dose escalating_study of rhIL-12_administered by intraperitoneal (IP)_infusion in adult_male_or female patients with measurable disseminated intraperitoneal cancer that is residual, recurrent or metastatic._Neither_a control_or_placebo_group will be utilized.